Patents by Inventor Bruce Furie

Bruce Furie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for reducing major thrombotic events in cancer patients
    Patent number: 12290527
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Grant
    Filed: January 12, 2024
    Date of Patent: May 6, 2025
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
  • COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS
    Publication number: 20240285659
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Application
    Filed: January 12, 2024
    Publication date: August 29, 2024
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Jeffrey I. ZWICKER, Bruce FURIE, Jack Davis STOPA, Robert FLAUMENHAFT
  • Compositions and methods for reducing major thrombotic events in cancer patients
    Patent number: 11872241
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: January 16, 2024
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Jeffrey I. Zwicker, Bruce Furie, Jack Davis Stopa, Robert Flaumenhaft
  • METHOD FOR TREATING SICKLE CELL DISEASE USING QUERCETIN-CONTAINING COMPOSITIONS
    Publication number: 20230029216
    Abstract: Disclosed are compositions and methods for treating sickle cell disease. Also disclosed are methods of treating sickle cell disease comprising administering to a subject in need thereof an effective amount of isoquercetin, vitamin B3, vitamin C, and optionally folic acid and wherein the effective amount is sufficient to halt progression of one or more of the symptoms of sickle cell disease.
    Type: Application
    Filed: July 15, 2022
    Publication date: January 26, 2023
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Jeffrey I. ZWICKER, Bruce FURIE, Robert FLAUMENHAFT
  • COMPOSITIONS AND METHODS FOR REDUCING MAJOR THROMBOTIC EVENTS IN CANCER PATIENTS
    Publication number: 20200171064
    Abstract: The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.
    Type: Application
    Filed: November 26, 2019
    Publication date: June 4, 2020
    Inventors: Jeffrey I. ZWICKER, Bruce FURIE, Jack Davis STOPA, Robert FLAUMENHAFT
  • Crystal structure of human factor VIII and uses thereof
    Publication number: 20090271163
    Abstract: The present invention provides crystals of human Factor VIII, in particular, a B-domain deleted human Factor VIII, and its three-dimensional structure. The present invention also provides the structural information of Factor VIII, and methods for identifying compounds that modulate Factor VIII activity, for determining structures of Factor VIII homologs or analogs, and for designing drug candidates for the treatment of hemophilia based on the structural information.
    Type: Application
    Filed: December 5, 2008
    Publication date: October 29, 2009
    Applicant: Wyeth
    Inventors: Jacky Ngo, Mingdong Huang, David A. Roth, Barbara C. Furie, Bruce Furie
  • Conopeptides
    Patent number: 6307014
    Abstract: Substantially pure conopeptides containing &ggr;-carboxyglutamic acid are disclosed.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: October 23, 2001
    Inventors: Bruce Furie, Barbara C. Furie, Johan Stenflo, Alan C. Rigby, Peter Roepstorff
  • Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Le.sup.x core component
    Patent number: 5807745
    Abstract: The present invention relates to a method of inhibiting (reducing or preventing) the interaction of a cell which bears a surface molecule that interacts with a ligand comprising a Le.sup.x core with its target ligand by contacting the cell with an inhibitor comprising a Lewis x (Le.sup.x) core. The invention further relates to a method of inhibiting (reducing or preventing) the interaction or adhesion of endothelial cells and/or platelets with leukocytes (i.e., white blood cells), especially with nonlymphocytic leukocytes such as neutrophils and monocytes, by contacting the endothelial cells and/or platelets with an inhibitor comprising a Le.sup.x core under conditions whereby adhesion is inhibited.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: September 15, 1998
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Bruce Furie, Barbara C. Furie, Eric Larsen, Theresa Palabrica, Susan A. Sajer, Denisa D. Wagner